Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants SAN JOSE, Calif., April 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a development and manufacturing agreement with Cytovance Biologics (), a leading full-service contr

Upcoming free, educational webinars from Xtalks will feature topics in cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, medical device, pharma manufacturing & supply chain and pharmaceutical regulation. TORONTO, April 1, 2026 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to sa

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology’s 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electronic

Company brings one of the only combined clinical and toxicological safety dataset in the hemp-derived CBD category into a new provider channel as CMS activates cannabinoid access within value-based care models CHARLOTTE, N.C., April 1, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), a leader in science-driven cannabinoid products, today announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organization

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Canada. At the event, Delcath’s Hepatic Delivery System for use in percutaneous hepatic perfusion will be featured in three presentations. On April 13, 2026, at 2:40 PM ET, Dr. Eric Weh

In this free webinar, learn the importance of measuring cognition in sleep medicine trials. The featured speaker will share considerations to understand the nature and magnitude of cognitive symptoms that can occur in adults with disorders of sleep or wakefulness. Attendees will see how cognitive tests can be used to better inform decision-making on the safety and efficacy of novel and licensed drugs. TORONTO, April 1, 2026 /PRNewswire/ -- Disruption to normal sleep/wake cycles, whether by disea

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability. Global pipelines for protein therapeutics, including complex biologics and biosimilars used to treat conditions ranging from cancer to autoimmune and rare diseases, continue to expand. This g

Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside cutting-edge research and clinical guidelines updates, during yearly event hosted by the National Comprehensive Cancer Network. ORLANDO, Fla., April 1, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a non-profit alliance of leading cancer centers—brought together more than a thousand oncology professionals at the NC

RALEIGH, N.C., April 1, 2026 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, committed to improving access to affordable medicines, today announced the re‑launch of Hydrochlorothiazide Tablets, USP in 12.5 mg, 25 mg, and 50 mg strengths. Hydrochlorothiazide tablets are approved as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy, along with edema due to various forms of renal dysfu

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux’s TRACTr platform, targeting an undisclosed solid tumor antigen expre